174 related articles for article (PubMed ID: 38011005)
1. Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study.
Shen W; Jin Y; Yu Y; Chen N; Fan Y
Thorac Cancer; 2024 Jan; 15(2):122-130. PubMed ID: 38011005
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis.
Li S; Zhou H; Zhang X; Bu B; Tao R; Zhang H; Yu J
Recent Pat Anticancer Drug Discov; 2023; 18(4):528-537. PubMed ID: 36415100
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
Jung HA; Kim M; Kim HS; Kim JH; Choi YH; Cho J; Park JH; Park KU; Ku BM; Park S; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2023 Feb; 18(2):223-231. PubMed ID: 36307042
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases.
Wang CL; Zhao YZ; Zhang Q; Zeng WQ; Jia TY; Zhu L; Fang WT; Fu XL
Anticancer Drugs; 2023 Aug; 34(7):852-856. PubMed ID: 36729892
[TBL] [Abstract][Full Text] [Related]
6. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review.
Zuo R; Zhang C; Lin L; Meng Z; Wang Y; Su Y; Abudurazik M; Du Y; Chen P
Thorac Cancer; 2020 Nov; 11(11):3383-3387. PubMed ID: 32997432
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study.
Xiang J; Si J; Hao Y; Wei J; Wang W; Guan Y; Xu C; Song Z
Transl Cancer Res; 2023 Mar; 12(3):550-557. PubMed ID: 37033336
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma.
Guan Y; Gu X; Si J; Xiang J; Wei J; Hao Y; Wang W; Sun Y
BMC Cancer; 2023 Jan; 23(1):16. PubMed ID: 36604688
[TBL] [Abstract][Full Text] [Related]
9. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.
Merveilleux du Vignaux C; Dansin E; Mhanna L; Greillier L; Pichon E; Kerjouan M; Clément-Duchêne C; Mennecier B; Westeel V; Robert M; Quantin X; Zalcman G; Thiberville L; Lena H; Molina T; Calcagno F; Fournel P; Mazières J; Besse B; Girard N
J Thorac Oncol; 2018 Nov; 13(11):1762-1770. PubMed ID: 30138763
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Wang Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Han S; Long J; Zhang Z; Fang J
Thorac Cancer; 2019 Jan; 10(1):17-23. PubMed ID: 30411854
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
13. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
Bellissimo T; Ganci F; Gallo E; Sacconi A; Tito C; De Angelis L; Pulito C; Masciarelli S; Diso D; Anile M; Petrozza V; Giangaspero F; Pescarmona E; Facciolo F; Venuta F; Marino M; Blandino G; Fazi F
Mol Cancer; 2017 May; 16(1):88. PubMed ID: 28486946
[TBL] [Abstract][Full Text] [Related]
14. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
[TBL] [Abstract][Full Text] [Related]
15. Treatments and outcomes of spinal metastasis from thymic epithelial tumors: 10-year experience with 15 patients in a single center.
Jia Q; Yang J; Hu J; Liu T; Yang C; Wei H; Yang X; Xiao J
Eur Spine J; 2019 Jun; 28(6):1520-1528. PubMed ID: 31065810
[TBL] [Abstract][Full Text] [Related]
16. Surgical outcomes of 215 patients with thymic epithelial tumors: A single-center experience.
Tian W; Sun Y; Wu Q; Jiao P; Ma C; Yu H; Huang C; Tong H
Thorac Cancer; 2020 Jul; 11(7):1840-1847. PubMed ID: 32384230
[TBL] [Abstract][Full Text] [Related]
17. Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center.
Jiao P; Tian WX; Wu FJ; Liu YX; Wu JY; Sun YG; Yu HB; Huang C; Wu QJ; Ma C; Li DH; Tong HF; Li J
J Cardiothorac Surg; 2023 Feb; 18(1):77. PubMed ID: 36810094
[TBL] [Abstract][Full Text] [Related]
18. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
[TBL] [Abstract][Full Text] [Related]
19. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
Wang CL; Gao LT; Lyu CX; Zhang Q; Zeng WQ; Fang WT; Zhu L; Fu XL
Med Oncol; 2022 Jan; 39(2):25. PubMed ID: 34982283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
